27,100 Shares in Vor Biopharma Inc. $VOR Acquired by Wellington Management Group LLP

Wellington Management Group LLP purchased a new position in shares of Vor Biopharma Inc. (NASDAQ:VOR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 27,100 shares of the company’s stock, valued at approximately $499,000.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Bank of New York Mellon Corp acquired a new stake in shares of Vor Biopharma in the second quarter worth $1,799,000. Bank of America Corp DE lifted its position in Vor Biopharma by 28,408.1% during the first quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock valued at $2,014,000 after purchasing an additional 112,496 shares during the period. Irenic Capital Management LP acquired a new position in Vor Biopharma during the first quarter valued at $583,000. Renaissance Technologies LLC purchased a new stake in Vor Biopharma in the first quarter valued at $2,298,000. Finally, Sei Investments Co. purchased a new stake in Vor Biopharma in the first quarter valued at $245,000. 97.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have weighed in on VOR. Weiss Ratings upgraded Vor Biopharma from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Tuesday, August 11th. Wedbush upped their target price on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. Wall Street Zen raised Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Finally, HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Vor Biopharma presently has a consensus rating of “Moderate Buy” and an average target price of $43.38.

Vor Biopharma Price Performance

Shares of NASDAQ VOR opened at $22.30 on Friday. The company’s fifty day moving average price is $21.71 and its 200 day moving average price is $17.44. Vor Biopharma Inc. has a 1 year low of $6.50 and a 1 year high of $49.95.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). As a group, analysts anticipate that Vor Biopharma Inc. will post -2.56 earnings per share for the current year.

Vor Biopharma Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor’s lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.